Assessment of the Consistency of Pharmacokinetic Parameters of LEVADEX™ (MAP0004, Orally Inhaled Dihydroergotamine) in Healthy Volunteers - Results from 3 Clinical Studies

被引：0
|
作者：
Forst, A. [1 ]
Iwashita, J. [1 ]
Kellerman, D. [1 ]
Kori, S. [1 ]
Thomas, T. [2 ]
Taylor, G. [3 ]
机构：
[1] MAP Pharmaceut Inc, Mountain View, CA USA
[2] Simbec Res Ltd, Merthyr Tydfil, South Wales, England
[3] Penreka Ltd, Cardiff, S Glam, Wales
来源：
HEADACHE | 2011年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：22 / 22
页数：1
相关论文
共 18 条
  • [1] Assessment of the consistency of pharmacokinetic parameters of levadex™ (map0004, orally inhaled dihydroergotamine) in healthy volunteers - results from 3 clinical studies
    Forst, A.
    Iwashita, J.
    Kellerman, D.
    Kori, S.
    Thomas, T.
    Taylor, G.
    CEPHALALGIA, 2011, 31 (01) : 82 - 82
  • [2] Assessing the Consistency of LEVADEX™ (MAP0004, Orally Inhaled Dihydroergotamine) Pharmacokinetic Parameters in Healthy Volunteers: Results from 3 Clinical Studies
    Forst, Amy
    Iwashita, Julie
    Kellerman, Don
    Kori, Shashidhar
    Thomas, Tracy
    Taylor, Glyn
    ANNALS OF NEUROLOGY, 2011, 70 : S64 - S64
  • [3] ASSESSING THE CONSISTENCY OF LEVADEX™ (MAP0004, ORALLY INHALED DIHYDROERGOTAMINE) PHARMACOKINETIC PARAMETERS IN HEALTHY VOLUNTEERS: RESULTS FROM 3 CLINICAL STUDIES
    Frost, A.
    Kellerman, D.
    Kori, S.
    Thomas, T.
    Taylor, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 197 - 197
  • [4] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX™ (MAP0004, orally inhaled dihydroergotamine) in Healthy Volunteers
    Kellerman, Don
    Forst, Amy
    Kori, Shashidhar
    Febbraro, Salvatori
    WuTann, Lan
    Thomas, Tracy
    Taylor, Glyn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1365 - 1366
  • [5] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX™ (MAP0004, Orally Inhaled DHE) in Healthy Volunteers
    Forst, A.
    Kellerman, D.
    Kori, S.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    HEADACHE, 2011, 51 : 20 - 20
  • [6] A drug interaction study assessing the effects of cyp3a4 inhibition on the pharmacokinetics of levadex™ (map0004 orally inhaled dhe) in healthy volunteers
    Forst, A.
    Kellerman, D.
    Kori, S.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    CEPHALALGIA, 2011, 31 (01) : 81 - 82
  • [7] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of MAP0004, an Orally Inhaled Formulation of Dihydroergotamine in Healthy Volunteers
    Forst, Amy
    Kellerman, Don
    Kori, Shashidhar
    Febbraro, Salvatori
    Tann, Lan
    Thomas, Tracy
    Taylor, Glyn
    NEUROLOGY, 2012, 78
  • [8] Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans
    Kellerman, D.
    Kori, S.
    Forst, A.
    Chang, J.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    Dodick, D. W.
    CEPHALALGIA, 2012, 32 (02) : 150 - 158
  • [9] Effects of a Supratherapeutic Dose of Investigational Orally Inhaled Dihydroergotamine (MAP0004) on QT Interval: A Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study in Healthy Volunteers
    Kori, Shashidhar
    Kellerman, Donald J.
    Voloshko, Polina
    Haugen, Gregory
    CLINICAL THERAPEUTICS, 2012, 34 (09) : 1920 - 1928
  • [10] Comparable Efficacy and Safety For Exploratory Endpoints Regardless of Pain Severity and Treatment Time after Migraine Onset: Results From a Phase 3 Trial of Orally Inhaled Dihydroergotamine (MAP0004) for the Acute Treatment of Migraine
    Tepper, S. J.
    Newman, L.
    Holdbrook, F.
    Earl, N. L.
    Davar, G.
    HEADACHE, 2014, 54 : 13 - 14
12